– USA, CA – Kronos Bio, Inc. (NASDAQ: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Dr. Marianne De Backer, Ph.D., to its board of directors. She will serve as a member of the compensation committee.
Dr. De Backer, a veteran biopharmaceutical executive, has more than two decades of experience in business development and commercial leadership in the healthcare industry.
“On behalf of the board of directors and senior management team at Kronos Bio, I am pleased to welcome Marianne to the board. Her significant experience in forging and managing strategic partnerships coupled with her broad business and commercial acumen and strong science background will be valuable as the company continues to grow,” said CEO, Dr. Norbert Bischofberger.
The company also announced that Dr. Rebecka Belldegrun has resigned from the board to pursue other opportunities.
Dr. Norbert Bischofberger added: “I would also like to thank Rebecka for her dedicated service to Kronos Bio. She has provided expert guidance and made numerous contributions to the company since our founding, and we wish her well.”
About Dr. Marianne De Backer
Dr. De Backer has been a strategist, scientist, business leader, dealmaker, and corporate investor in the healthcare industry. She has been directly accountable for more than 200 strategic alliances in healthcare, some of which have led to newly approved medicines now available to patients. Dr. De Backer is currently Chief business officer and executive vice president, Strategy and Business Development and Licensing, at Bayer AG, and a member of the Executive Committee of Bayer Pharmaceuticals.
Before joining Bayer in 2019, she spent more than 20 years at the Johnson & Johnson family of companies. She started as a scientist and scientific group leader, during which time her work resulted in multiple patents. She progressed through commercial positions internationally, including leading a sales and marketing business unit responsible for several therapies, culminating as senior vice president, M&A Operations, Divestitures, and Janssen Business Development.
She currently serves on the boards of directors of the Gladstone Foundation and Arrowhead Pharmaceuticals.
“Kronos Bio is at an important juncture as it advances toward planned clinical testing of two investigational therapies that have the potential to transform treatment outcomes for patients with cancer,” said Dr. De Backer. “I look forward to helping guide the company as it grows and seeks to become the leader in targeting dysregulated transcription.”
Dr. De Backer holds an M.S. in molecular biology from the Vrije Universiteit Brussels, an M.S. in engineering and biochemistry and a Ph.D. in biotechnology from the University of Ghent, and an MBA from the Rotterdam School of Management at Erasmus University.
About Kronos Bio, Inc.
Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio’s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in development for the frontline treatment of NPM1-mutated acute myeloid leukemia. The company is also developing KB-0742, an oral inhibitor of cyclin-dependent kinase 9, for the treatment of MYC-amplified solid tumors.
Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass.
For more information: https://kronosbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
